Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim
News Jan 15, 2015
Oxford BioTherapeutics has announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration. The target was discovered using Oxford BioTherapeutics’ proprietary OGAP® system, which incorporates one of the world’s largest proprietary proteomic databases, integrating clinical, experimental and expression data.
This represents the first option exercised under the companies’ oncology target discovery and validation collaboration established in 2013. Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target. Oxford BioTherapeutics will receive development and regulatory milestone payments, and royalties on any future product sales.
“We are delighted to have reached this important milestone in the collaboration with Boehringer Ingelheim, which validates both our ongoing collaboration with a world-leading oncology company and our unique OGAP® target discovery system,” said Dr Christian Rohlff, CEO of Oxford BioTherapeutics.
Dr Rohlff continued, “Antibody therapeutics are a focus area for oncology R&D, and the selection of their targets is important for their success. With our world-leading targeting technology and in-house pipeline of novel antibody-drug conjugates, Oxford BioTherapeutics is rapidly establishing its position as a partner of choice for the development of new generation cancer therapeutics.”
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018